Advanced Cell Technology, Inc. (“ACT”;
or the “Company”), a leader in the field of regenerative medicine, announced today that the company is a sponsor of the 2012 World Stem Cell Summit , Dec. 3-5 at the Palm Beach County Convention \Center in West Palm Beach, Florida. The Company will host an “Experts Luncheon” and chairman and CEO Gary Rabin and director of business development Matthew Vincent, Ph.D., will also serve on panels at the event.
On Monday, Dec. 3, Dr. Vincent will host a “Conversation with Experts Luncheon” at which he will meet with conference attendees to discuss the Company’s programs and the future of regenerative medicine and stem cell therapies.
Also on Monday, Dec. 3, at 4:00 p.m. EST Dr. Vincent will serve on a panel titled
“Understanding the Legal and Policy Challenges to Stem Cell Research” and on Tuesday, Dec. 4, at 10:30 a.m. EST Mr. Rabin will be part of a “Clinical Trial Update” session, providing an update on the Company’s three ongoing human clinical trials for dry age-related macular degeneration (dry AMD) and Stargardt’s disease using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.
The full conference agenda is available
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.